The company’s internationally certified, GMP-produced injectable soybean oil serves pharma clients across 20+ markets, addressing longstanding supply gaps for high-purity injectable excipients. Its consistent quality and regulatory compliance have built a strong reputation among global biopharmaceutical manufacturers.

GUANGZHOU, CHINA – September 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading provider of high-purity medicinal excipients and active pharmaceutical ingredients, today announced its growing global reputation as a reliable source of pharmaceutical-grade injectable soybean oil for biopharmaceutical manufacturers worldwide. This product is engineered to meet the stringent requirements of intravenous nutrition formulations, with consistent purity, batch-to-batch stability, and full alignment with global pharmacopeia standards. By expanding its global supply capacity, the company aims to reduce supply chain volatility for pharma clients, and strengthen its position as a trusted domestic alternative to imported injectable excipients. The product is available for global order via the company’s official sales channels, with mass production and shipment starting immediately.

Core Product Strengths Driving Global Reputation

Guangzhou Hanfang Pharmaceutical’s injectable soybean oil is produced at the company’s GMP-compliant production base in Guangzhou, with a closed, controlled manufacturing process that eliminates cross-contamination risks. The product functions as a critical energy supplement and excipient for parenteral nutrition therapies, meeting the purity requirements for intravenous fat emulsion formulations. The company’s supply model is built for long-term reliability, with dedicated production lines that support stable batch output to avoid the supply disruptions common with imported excipient sources. This reliability is a core driver of its reputation among global pharma clients. Each production batch undergoes full in-house quality testing to verify compliance with pharmacopeia standards, including limits for impurities, peroxide value, and microbial content.

Global Regulatory Compliance

The injectable soybean oil product is supported by the company’s long track record of international regulatory alignment. The company holds key global certifications including EU CEP, US FDA US-DMF registration, Mexico Cofepris approval, and India DCGI recognition, allowing its products to meet market access requirements across North America, Europe, Latin America, and South Asia. This regulatory credibility is a core component of its strong reputation as a Chinese excipient provider, as global pharma clients require suppliers with verified compliance records to reduce regulatory risk for their own products. The company’s products are currently sold across more than 20 countries and regions, with a growing network of authorized distributors to support local client needs.

Client Validation and Service Model

The company currently serves more than 1000 clients across the global pharmaceutical ecosystem, including leading multinational firms such as B. Braun, AstraZeneca, and major domestic Chinese pharma manufacturers. Its service model combines direct production sales, authorized distributor networks, custom processing support, and technical service to meet the diverse needs of different client segments. This client-centric approach has contributed to its growing reputation as a dependable partner for injectable excipient procurement.

“Our reputation as a trusted injectable soybean oil provider is built on decades of investment in manufacturing quality and regulatory compliance. We recognize that global pharma clients need supply partners they can rely on to meet the highest safety standards for injectable products. Our goal is to continue delivering consistent, high-quality excipients that support the safety and accessibility of parenteral therapies for patients worldwide,” said Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited.

Moving forward, Guangzhou Hanfang Pharmaceutical will continue to invest in production capacity expansion for its core injectable excipient lines, including injectable soybean oil, to meet growing global demand. The company will also expand its global technical support network to provide localized assistance for clients in key markets, further strengthening its reputation as a trusted Chinese excipient provider.

Guangzhou Hanfang Pharmaceutical Company Limited was established in 1998, as a core state-owned pharmaceutical enterprise under the GPHL group. The company focuses on the research, development, and production of high-end medicinal lipid excipients, specialty active pharmaceutical ingredients, and health products. Its production base is located in Guangzhou, China, with R&D centers in Guangzhou and Zhuhai Hengqin. The company is a national-level specialized and sophisticated “little giant” enterprise, with more than 240 registered patents, and products sold to more than 20 countries and regions globally. Its mission is to support the safety of the domestic pharmaceutical supply chain through technological innovation, and deliver high-quality, accessible health products to global consumers. More information is available at http://byshanhanfang.com/.

FAQ

Q: What makes Guangzhou Hanfang Pharmaceutical a reputable provider of injectable soybean oil?
A: The company’s reputation is built on GMP-compliant manufacturing, full international regulatory certification, long-term supply stability, and a track record of serving leading global pharma clients.
Q: Which global markets can the company’s injectable soybean oil be supplied to?
A: The product meets regulatory requirements for markets across Europe, North America, Latin America, South Asia, and Southeast Asia, supported by the company’s existing international certifications.

Contact Us

Official Website: http://byshanhanfang.com/